Sant Pau - Institut de Recerca

Principales líneas de investigación

Terapia biológica en dermatología.
Estudios de asociación de genoma completo en la psoriasis
Opciones de tratamiento médico y físico para tumores vasculares.
Estudios psicopatológicos de pacientes con trastornos dermatológicos crónicos.
Estudio de la inmunidad innata y adquirida en enfermedades dermatológicas mediadas inmunológicamente.

Retos

Garantizar una infraestructura de investigación clínica y personal estables.
Fomentar la colaboración científica con otros grupos del Instituto.

Coordinación del grupo

PUIG SANZ, LUIS FGS
lpuig@santpau.cat

Miembros

Altemir Vidal, Arcadi FGS
Bravo Gonzalez, Marina IR
Diaz-Salazar Monreal, Maria IR
Flores Climente, Victor Adrian IR
Fuentes Garcia, Ruben IR
Garces Gatnau, Joan Ramon FGS
Garcia Muret, Maria Pilar FGS
Gely Vila, Cristina IR
Iznardo Ruiz, Helena FGS
Lopez Ferrer, Anna FGS
Lopez Sanchez, Cristina FGS
Morales Munera, Caridad Elena FGS
Roe Crespo , Esther FGS
Ruiz Salas, Veronica FGS
Rusiñol Batlle, Lluis FGS
Serra Baldrich, Esther FGS
Spertino , Jorge Luis FGS
Vilarrasa Rull, Eva FGS
Yelamos Pena, Oriol FGS

Publicaciones 2022

(JIF 2022)

Amat V, Lopez C, Tubau C, Puig L, Serra E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1). DOI:10.1111/cod.14101. PMID:35277988. IF:5,5 (Q1/1D). Document Type: Editorial material.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12). DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3,4 (Q2/3D). Document Type: Letter.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3,4 (Q2/3D). Document Type: Article.
Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Meglio PD, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Smith CH, Galloway JB, Mahil SK, PsoProtect G. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2). DOI:10.1111/bjd.21042. PMID:35104366. IF:10,3 (Q1/1D). Document Type: Letter.
Bes M, Costafreda MI, Riveiro M, Piron M, Rico A, Quer J, Puig L, Sauleda S. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. EMERGING INFECTIOUS DISEASES. 2022; 28(1). DOI:10.3201/eid2801.211466. PMID:34932460. IF:11,8 (Q1/1D). Document Type: Article.
Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4). DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13,8 (Q1/1D). Document Type: Article.
Canal E, Bosch X, Belinchon I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.006. PMID:35697407. Document Type: Review.
Carmona E, Iznardo H, Puig L. Retiform purpura in an 80-year-old woman. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2022; 61(10). DOI:10.1111/ijd.16120. PMID:35106756. IF:3,6 (Q1/3D). Document Type: Editorial material.
Carrascosa JM, Puig L, Romero IB, Salgado L, del Alcazar E, Lencina J, Moreno D, de la Cueva P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliograficas. 2022; 113(6):T583-T609. DOI:10.1016/j.ad.2022.01.024. PMID:35748004. Document type: Article/Practice Guideline.
Catala A, Munoz C, Galvan C, Riesco MR, Nebreda DR, Sola A, Giavedoni P, Llamas M, Gonzalez C, Cubiro X, Ruiz R, Gomez S, Mateo MPG, Pesque D, Marcantonio O, Fernandez D, Romani J, Pena NI, Gonzalez LC, Tercedor J, Carretero G, Masat T, Rodriguez P, Gimenez AM, Utrera M, Laguna EV, Menendez A, Lasser ES, Iglesias M, Naranjo LA, Hiltun I, Marco EC, Olabarrieta IP, Escobedo SM, Garcia X, Gutierrez MJC, Baeza G, Camps LB, Toledo T, Guilabert A. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(1). DOI:10.1111/bjd.20639. PMID:34254291. IF:10,3 (Q1/1D). Document Type: Article.
Chabra S, Gill BJ, Gallo G, Zhu DT, Pitou C, Payne CD, Accioly A, Puig L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6). DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3,8 (Q2/4D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Acosta EH, Vidal D, Vilarrasa E, Rivera R, De P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Rodriguez OB, Feltes R, Riera J, Dauden E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12):e15929. DOI:10.1111/dth.15929. PMID:36223184. IF:3,6 (Q1/3D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Herrera E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Baniandres O, Feltes R, Alsina M, Dauden E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8):e15653. DOI:10.1111/dth.15653. PMID:35731640. IF:3,6 (Q1/3D). Document Type: Article.
Colmenero M, del Boz J, Wittel JB, Roe E, Feito M, Vicente MA, Martin A, Perez S, Azon A, Valdivielso M, Torrelo A, Moya A, Campos M, Garnacho G, Defez J, Casano AV, Tercedor J, Alcala R, Gonzalez MA, Giacaman A, Hernandez A, Garcia MTM, Bauza A, Dominguez J, Garcia I, Grau M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4). DOI:10.1111/pde.15015. PMID:35504688. IF:1,5 (Q4/8D). Document Type: Article.
Cubiro X, Garcia C, Tubau C, Puig L. Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology Venereology & Leprology. 2022; 88(1). DOI:10.25259/IJDVL_63_2021. PMID:34623049. IF:2,9 (Q2/4D). Document Type: Letter.
de Bruin MS, Serra E, Barbarot S, Grond S, Schuster C, Petto H, Capron JP, Raibouaa A, Werfel T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6). DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3,4 (Q2/3D). Document Type: Article.
de Frutos JO, Carretero G, de Lucas R, Puig S, Serra E, Castro SG, Laserna FR, Loza E, Silvestre JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5). DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2,9 (Q2/4D). Document Type: Article.
del Alcazar E, Lopez A, Martinez A, Julia M, Ruiz R, Fernandez LR, Notario J, Llamas M, Ferran M, Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6). DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2,9 (Q2/4D). Document Type: Letter.
del Alcazar E, Lopez A, Martinez A, Ruiz R, Llamas MD, Rocamora V, Julia M, Notario J, Fernandez LR, Sahuquillo A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P, Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2):e15231. DOI:10.1111/dth.15231. PMID:34820971. IF:3,6 (Q1/3D). Document Type: Article.
Fernandez A, Ballart C, Munoz J, Basarte L, Lobato G, Arnau A, Abras A, Tebar S, Llovet T, Lami P, Pratlong F, Alsina M, Roe E, Puig L, Munoz C, Gallego M. Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. Transboundary and Emerging Diseases. 2022; 69(3). DOI:10.1111/tbed.14107. PMID:33864706. IF:4,3 (Q1/1D). Document Type: Article.
Fernandez MT, Carrato C, Saenz X, Musulen E, Fuente MJ, Puig L. MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. ARCHIVES OF DERMATOLOGICAL RESEARCH. 2022; 314(8). DOI:10.1007/s00403-021-02288-x. PMID:34647185. IF:3 (Q2/4D). Document Type: Article.
Gamissans M, Giavedoni P, Roe E, Sanchez J, Quintana M, Garbayo P, Vidal D, Riera N, Lopez C, Romani J, Wortsman X. Multicentric Study on High-Frequency Ultrasound Characterization of Calcium Deposits in Dermal and Subcutaneous Calciphylaxis and Calcinosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2022; 41(8). DOI:10.1002/jum.15878. PMID:34755910. IF:2,3 (Q2/5D). Document Type: Article.
Gimenez A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, Munoz F, Pedraz J, Serra E, Tejedor M, Velasco M, Terradas P, Labrador M. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022; 32(3). DOI:10.18176/jiaci.0661. PMID:33349612. IF:7,2 (Q1/2D). Document Type: Article.
Iznardo H, Bredrup C, Bernal S, Gladkauskas T, Mascaro JM, Roe E, Baselga E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4). DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2,8 (Q3/6D). Document Type: Article.
Iznardo H, Puig L. Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4). DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5,1 (Q2/3D). Document Type: Review.
Iznardo H, Puig L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16):9479. DOI:10.3390/ijms23169479. PMID:36012744. IF:5,6 (Q1/3D). Document Type: Review.
Iznardo H, Vilarrasa E, Roe E, Puig L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18116. PMID:35353931. IF:9,2 (Q1/1D). Document Type: Letter.
Krueger J, Puig L, Thaci D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7,3 (Q1/1D). Document Type: Review.
Le AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7,3 (Q1/1D). Document Type: Review.
Lebwohl M, Langley RG, Paul C, Puig L, Reich K, van de Kerkhof P, Wu HL, Richter S, Jardon S, Gisondi P. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00635-4. PMID:34704231. IF:3,4 (Q2/3D). Document Type: Article.
Lebwohl M, Soliman AM, Yang HB, Wang J, Freimark J, Puig L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(4). DOI:10.1080/09546634.2021.1919287. PMID:33899655. IF:2,9 (Q2/4D). Document Type: Article.
Lopez A, Laiz A, Puig L. Psoriatic arthritis. MEDICINA CLINICA. 2022; 159(1). DOI:10.1016/j.medcli.2022.01.024. PMID:35525675. IF:3,9 (Q2/4D). Document Type: Review.
Lopez A, Vilarrasa E, Armesto S, Santos J, Galache C, Carretero G, Sahuquillo A, Salgado L, del Alcazar E, Gonzalez A, Martorell A, Rivera R, Mitxelena J, Mateu A, Belinchon I, Llamas M, Riera J, Lazaro A, Lopez JL, Gich I, Puig L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11):e15831. DOI:10.1111/dth.15831. PMID:36109488. IF:3,6 (Q1/3D). Document Type: Letter.
Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7,3 (Q1/1D). Document Type: Review.
Medina D, Riera P, Pages N, Masip M, Lopez A, Vilarrasa E, Puig L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3). DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2,4 (Q3/8D). Document Type: Article.
Medrano RM, Estebaranz JLL, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, De Eusebio E, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, De la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Ruiz V, Sanchez P, Botella R, Gonzalez B, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, REGESMOHS Spanish Registry Mohs SU. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-Sifiliograficas. 2022; 113(5). DOI:10.1016/j.ad.2022.01.035. Document Type: Article.
Melé G, Serra E, Spertino J, Guilarte M, Ribó P, Lleonart R, Figueras I, Bonfill M, Depreux N, Sala A, Bielsa I, Baliu C, Sanmartín V, Garcia X, Expósito V, Garnica D, Diaz MC, Gómez S, Gich I, Giménez A. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(5). DOI:10.1684/ejd.2022.4334. PMID:36468733. IF:2,5 (Q2/5D). Document Type: Article.
Oro M, Gonzalez B, Sanmartin O, Garces JR, Rodriguez MA, Ruiz V, de Eusebio E, Minano R, Escutia B, Cortizas CF, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, de la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Vilarrasa E, Sanchez P, Lopez JL, Botella R, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, Florez A. Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(1). DOI:10.1111/jdv.17597. PMID:34374137. IF:9,2 (Q1/1D). Document Type: Letter.
Pereyra J-J, Herranz P, Figuras I, Perez B, Elosua M, Munera M, Melgosa J, Zaragoza V, Silvestre JF, Campos M, Guilabert A, Miquel J, Alcantara S, De La Cueva P, Serra E, Armario JC. Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort – Real Life: Fifty-Two-Week Follow-up Results. Dermatitis. 2022; 33(6). DOI:10.1097/DER.0000000000000958. PMID:36125777. IF:5,2 (Q1/2D). Document Type: Letter.
Pinter A, Puig L, Schakel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18376. PMID:35766124. IF:9,2 (Q1/1D). Document Type: Article.
Piron M, Jane M, Ciruela P, Basile L, Martinez A, Puig L, Bes M, Sauleda S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5). DOI:10.2450/2022.0232-21. PMID:35175189. IF:3,7 (Q2/4D). Document Type: Article.
Piron M, Salvador F, Caballero E, Sanchez A, Bes M, Casamitjana N, Puig L, Molina I, Sauleda S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9):1975. DOI:10.3390/v14091975. PMID:36146780. IF:4,7 (Q2/5D). Document Type: Article.
Puig L, Costanzo A, Munoz EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5). DOI:10.1111/bjd.20963. PMID:34939663. IF:10,3 (Q1/1D). Document Type: Review.
Puig L. Psoriasis treatment: no more room on the summit?. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(6). DOI:10.1111/bjd.21848. PMID:36065496. IF:10,3 (Q1/1D). Document Type: Editorial material.
Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3). DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2,9 (Q2/4D). Document Type: Article.
Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Saday KK, Warren RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18068. PMID:35279890. IF:9,2 (Q1/1D). Document Type: Article.
Reolid A, Armesto S, Sahuquillo A, Torres T, Feltes R, Vilarrasa E, Belincho I, de la Cueva P, Rodriguez L, Romero A, Vidal D, Coto P, Herrera E, Riera J, Salgado L, Llamas M, Dauden E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3). DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13,8 (Q1/1D). Document Type: Letter.
Reymundo A, Vilarrasa E, Baniandrés O, Rodríguez L, Feltes R, Llamas M, Daudén E. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(10). DOI:10.1111/jdv.18317. PMID:35689497. IF:9,2 (Q1/1D). Document Type: Letter.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Trakatelli M, Puig L, Stratigos A, EADV Burden Skin Dis Project T. Prevalence of most common skin diseases in Europe: a population-based study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(7). DOI:10.1111/jdv.18050. PMID:35274366. IF:9,2 (Q1/1D). Document Type: Article.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:3,4 (Q2/3D). Document Type: Article.
Rusinol L, Camina G, Puig L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12). DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4,6 (Q2/3D). Document Type: Article.
Sánchez G, Puig L. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6). DOI:10.1016/j.piel.2021.06.020. Document Type: Article.
Sans L, Figueras I, Bonfill M, De Jesus C, Garcia I, Guilabert A, Curto L, Bertolin M, Ferran M, Serra E, Zalewska A, Wang YH, Howell MD, Pujol RM, Santamaria LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11). DOI:10.1111/all.15424. PMID:35773619. IF:12,4 (Q1/1D). Document Type: Letter.
Sanz C, Nomdedeu M, Pereira A, Sauleda S, Alonso R, Bes M, Brillembourg H, Garcia C, Millan A, Martinez N, Piron M, Puerta P, Puig L, Rico V, Soriano A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5). DOI:10.1111/trf.16863. PMID:35338710. IF:2,9 (Q3/7D). Document Type: Article.
Serra E, Santamaria LF, Silvestre JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7). DOI:10.1016/j.ad.2021.12.014. PMID:35842249. Document Type: Review.
Thaci D, Gerdes S, Du KG, Perrot JL, Puig L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10). DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3,4 (Q2/3D). Document Type: Article.
Thaci D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye JN, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2). DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3,4 (Q2/3D). Document Type: Article.
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova I, Arents BWM, Bauer A, Brans R, Cannavo A, Christoffers WA, Crépy M-N, Elsner P, Fartasch M, Filon FL, Giménez AM, Gonçalo M, Guzmán MG, Hamann CR, Hoetzenecker W, Johansen JD, John SM, Kunkeler ACM, Hadzavdic SL, Molin S, Nixon R, Oosterhaven JAF, Rustemeyer T, Serra E, Shah M, Simon D, Skudlik C, Spiewak R, Valiukeviciene S, Voorberg AN, Weisshaar E, Agner T. Guidelines for diagnosis, prevention, and treatment of hand eczema. CONTACT DERMATITIS. 2022; 86(5). DOI:10.1111/cod.14035. PMID:34971008. IF:5,5 (Q1/1D). Document Type: Article/Practice Guideline.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, del Alcazar E, Rull EV, Llamas M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7,3 (Q1/1D). Document Type: Article.
Tubau C, Cubiro X, Amat V, Garcia C, Puig L, Roe E. Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal Of Ultrasound. 2022; 25(4). DOI:10.1007/s40477-022-00665-4. PMID:35397096. Document Type: Article.
Van AM, Menting SP, Gyulai R, Iversen L, Van Der Kraaij GE, Middelkamp MA, Warren RB, Spuls PI, Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse A-C, Carija A, Akman A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado C, Hong C-H, et al. [Vilarrasa E, Puig L]. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5). DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10,9 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9). DOI:10.1111/jdv.18345. PMID:35980214. IF:9,2 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18429. PMID:36056736. IF:9,2 (Q1/1D). Document Type: Article.
Zachariae C, Mrowietz U, Strodl J, Puig L. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4). DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2,5 (Q2/5D). Document Type: Article.
Zozaya N, Abdalla F, Zamora SA, Filgueiras JB, Carrillo JMC, Sanchez OD, Sinisterra FD, Garcia A, Pinto PH, Manfredi A, Olmos JM, Luna PMD, Puig L, Ros S, HIdalgo A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6). DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2,3 (Q3/7D). Document Type: Article.
Zozaya N, Villoro R, Abdalla F, Alfonso S, Balea J, Carrascosa JM, Delgado O, Dolz F, Garcia A, Herranz P, Manfredi A, Martinez J, Morales De los Rios Luna P, Puig L, Ros S, Hildago A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102:adv00678. DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3,6 (Q1/3D). Document Type: Article.

Publicaciones 2021

Amat V, Agut E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211055920. DOI:10.1177/20406223211055920. PMID:34840709. IF:4,970.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Puig L, Augustin M. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00511-1. PMID:33788177. IF:3,661.
Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(4). DOI:10.1111/jdv.17075. PMID:33533553. IF:9,228.
Buhl T, Rosmarin D, Serra E, Fernandez P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00534-8. PMID:33899152. IF:3,661.
Campos MC, Tubau C, Segura S, Gonzalez M, Iglesias M, Fernandez MT, Garcia MP, Mozos A. Oral submucous fibrosis presenting with histopathological lichenoid changes as predominant feature: Report of five cases and review of the literature. JOURNAL OF CUTANEOUS PATHOLOGY. 2021; 48(11). DOI:10.1111/cup.14084. PMID:34151457. IF:1,458.
Carretero G, Carrascosa JM, Puig L, Sánchez-Carazo JL, López-Ferrer A, Cueva P, Soria C, Rivera R, Belinchón I; Psoriasis Group of the Spanish Academy of Dermatology, Venereology. Definition of minimal disease activity in psoriasis. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(2):422-430. DOI:10.1111/jdv.16564. PMID: 32367536. IF:9,228.
Cubiro X, Garcia C, Morales CE, Roe E, Riera A, Mora JM, Iriarte A, Puig L, Baselga E. Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. Dermatologic Therapy. 2021; 34(6):e15124. DOI:10.1111/dth.15124. PMID:34486206. IF:3,858.
de Bruin M, Merola JF, Hong CH, Baldrich ES, Ettler K, Sierka D, Delevry D, Chen Z, Rossi AB. Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective. Dermatology and Therapy. 2021; 11(6). DOI:10.1007/s13555-021-00621-w. PMID:34767181. IF:3,661.
Galvan C, Mitja O, Esteban S, Kafulafula J, Phiri T, Navarro I, Roman C, Mtenje H, Thauzeni G, Harawa E, Kaluzi S, Diere M, Mkandawire M, Malizani S, Chifundo A, Utrera M, Roncero M, Martin SL, Vilanova I, Petiti GH, Aranda MVD, Perez NN, Gomez MR, Iranzo P, Garcia PE, De Troya M, Gomez JR, Cardenoso E, Truyols SL, Unanue LA, et al. [Cubiro X, Lopez C]. A facility and community-based assessment of scabies in rural Malawi. PLoS Neglected Tropical Diseases. 2021; 15(6):e0009386. DOI:10.1371/journal.pntd.0009386. PMID:34061851. IF:4,781.
Garcia C, Roe E, Rodriguez B, Amat V, Cubiro X, Puig L, Boronat S. A case report of PHF6 mosaicism: Beyond the classic Borjeson-Forssman-Lehmann syndrome. PEDIATRIC DERMATOLOGY. 2021; 38(4). DOI:10.1111/pde.14636. PMID:34041787. IF:1,997.
Garcia J, Delgadillo J, Vilarrodona A, Querol S, Ovejo J, Coll R, Millan A, Madrigal A, Soria G, Vidal F, Vives J, Herrero MJ, Lopez I, Sauleda S, Contreras E, Grifols JR, Guasch R, Tahull E, Puig L, Masip A, Argelagues E, Muniz E. SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfusion. 2021; 19(2). DOI:10.2450/2021.0259-20. PMID:33539280. IF:5,752.
García-Martínez FJ, Vilarrasa E, Salgado-Boquete L, Martorell A, Pascual JC, Hernández-Martín Á, Silvente C, Ciudad-Blanco C, Andrés Esteban E, Alfageme-Roldán F. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021y;32(3):286-290. DOI:10.1080/09546634.2019.1655524. PMID: 31402725. IF:3,230.
Girolomoni G, de Bruin M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211002979. DOI:10.1177/20406223211002979. PMID:33854747. IF:4,970.
Gomis-Pastor M, Mirabet Perez S, Roig Minguell E, Brossa Loidi V, Lopez Lopez L, Ros Abarca S, Galvez Tugas E, Mas-Malagarriga N, Mangues Bafalluy MA. Mobile Health to Improve Adherence and Patient Experience in Heart Transplantation Recipients: The mHeart Trial. Healthcare (Basel). 2021;9(4):463. DOI:10.3390/healthcare9040463. PMID: 33919899. IF:3,160.
González-Manso A, Agut-Busquet E, Romaní J, Vilarrasa E, Bittencourt F, Mensa A, Cantó E, Aróstegui JI, Vidal S. Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis. Dermatology. 2021;237(3):365-371. DOI:10.1159/000511045. PMID: 33171462. IF:5,197.
Iznardo H, Baselga E, Mozos A, Szafranska J, Orellana R, Roe E. Net-like superficial lymphatic malformation. PEDIATRIC DERMATOLOGY. 2021; 38(2). DOI:10.1111/pde.14526. PMID:33486776. IF:1,997.
Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211037846. DOI:10.1177/20406223211037846. PMID:34408825. IF:4,970.
Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(9):4344. DOI:10.3390/ijms22094344. PMID:33919434. IF:6,208.
Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Review of Clinical Immunology. 2021; 17(2). DOI:10.1080/1744666X.2021.1886081. PMID:33538202. IF:5,124.
Julia A, Martinez SH, Domenech E, Canete JD, Ferrandiz C, Tornero J, Gisbert JP, Fernandez A, Dauden E, Barreiro M, Perez C, Queiro R, Lopez FJ, Carazo JLS, Mendoza JL, Alperi M, Montilla C, Venegas JJP, Munoz F, Castaneda S, Lasanta ML, Marsal S, Fonseca E, Rodriguez J, Carreira P, Garcia V, Pinto JA, Puig L, Ricart E, Blanco F, Gratacos J, et al. [Garcia E, Diaz C]. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2021; 75(9). DOI:10.1038/s41430-021-00913-6. PMID:33893449. IF:4,884.
Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, Abuzakouk M, Agondi RC, Al-Ahmad M, Altrichter S, Arnaout R, Arruda LK, Asero R, Bauer A, Ben-Shoshan M, Bernstein JA, Bizjak M, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Busse P, Campos RA, Carne E, Conlon N, Criado RF, de Souza Lima EM, Demir S, et al. [Serra-Baldrich E]. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76(3):816-830. DOI:10.1111/all.14687. PMID: 33284457. IF:14,710.
Lambert J, Hansen JB, Sohrt A, Puig L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00545-5. PMID:33988818. IF:3,661.
Llao J, Masnou H, Romero C, Bargallo A, Gely C, Manosa M, Gordillo J, Garcia E, Domenech E. Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2021; 33(6). DOI:10.1097/MEG.0000000000001799. PMID:32804842. IF:2,586.
Lopez C, Falla LM, Roe E, Arostegui JI, Mozos A, Bernal S, Iznardo H, Baselga E. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. JOURNAL OF DERMATOLOGY. 2021; 48(6). DOI:10.1111/1346-8138.15673. PMID:33543522. IF:3,468.
Lopez C, Romani J, Garbayo P, Agut E. Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. JOURNAL OF DERMATOLOGY. 2021; 48(4). DOI:10.1111/1346-8138.15728. PMID:33547675. IF:3,468.
Lopez C, Romani J, Roe E, Giavedoni P, Vidal D, Wortsman X. Ultrasonographic patterns of cutaneous sarcoidosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2021; 40(11). DOI:10.1002/jum.15631. PMID:33459396. IF:2,754.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di P, Langan SM, Capon F, et al.; PsoProtect GRP. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2021; 147(1). DOI:10.1016/j.jaci.2020.10.007. PMID:33075408. IF:14,290.
Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, de la Cruz C, Di P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, et al.; PsoProtect CORE GRP. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(1). DOI:10.1111/bjd.19755. PMID:33368145. IF:11,113.
Marron SE, Gomez M, Aragones LT, Goni A, Vilarrasa E, Diaz RM, Garcia FJ, Campos R, Fuentelsaz V, Gilaberte Y, Gracia T, Morales AM, Ros S, Madrid MB, Puig L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv00529. DOI:10.2340/00015555-3905. PMID:34427316. IF:3,875.
Massey PR, Schmults CD, Li SJ, Arron ST, Asgari MM, Bavinck JNB, Billingsley E, Blalock TW, Blasdale K, Carroll BT, Carucci JA, Chong AH, Christensen SR, Chung CL, DeSimone JA, Ducroux E, Escutia B, Ferrandiz C, Fox MC, Genders RE, Geusau A, Gjersvik P, Hanlon AM, Harken E, Hofbauer GFL, Hopkins RS, Leitenberger JJ, Loss MJ, Del Marmol V, et al. [Ruiz V]. Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients A Delphi Consensus Statement. JAMA Dermatology. 2021; 157(10). DOI:10.1001/jamadermatol.2021.3180. PMID:34468690. IF:11,816.
Mogedas A, Agut E, Marsal MY, Aguilar JL, de la Torre OE. Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021; 79(12). DOI:10.1016/j.joms.2021.07.009. PMID:34391723. IF:2,136.
Muniz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, Millan A, Ene G, Ramiro L, Maglio L, Garcia N, Pinacho A, Jaramillo A, Pero A, Artaza G, Valles R, Sauleda S, Puig L, Contreras E. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfusion. 2021; 19(1). DOI:10.2450/2020.0256-20. PMID:33196417. IF:5,752.
Munoz FZ, Rios M, Roe E, Bernabeu J, Montserrat MT, Puig L, Gich I, Baselga E. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage A Randomized Clinical Trial. JAMA Dermatology. 2021; 157(5). DOI:10.1001/jamadermatol.2021.0596. PMID:33825828. IF:11,816.
Nieto LM, Ciudad C, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, de Eusebio E, Minano R, Escutia B, Gonzalez B, Artola JL, Rubio AA, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, Dobao PD, Navarro R, Suarez R, Carnero L, Vazquez H, Barchino L, Ruiz V, Sanchez P, Lopez JL, Botella R, Feal C, Calatayud AM, Gil P, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. EXPERIMENTAL DERMATOLOGY. 2021; 30(5). DOI:10.1111/exd.14291. PMID:33523531. IF:4,511.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(6). DOI:10.1111/bjd.20595. PMID:34157132. IF:11,113.
Papp KA, Soliman AM, Done N, Carley C, Wirtz EL, Puig L. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00550-8. PMID:34019229. IF:3,661.
Pereira MP, Zeidler C, Wallengren J, Halvorsen JA, Weisshaar E, Garcovich S, Misery L, Brenaut E, Savk E, Potekaev N, Lvov A, Bobko S, Szepietowski JC, Reich A, Bozek A, Legat FJ, Metz M, Streit M, Serra E, Goncalo M, Storck M, Nau T, Hoffmann V, Steinke S, Greiwe I, Dugas M, Augustin M, Stander S, European Prurigo Project Epp C. Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv000403. DOI:10.2340/00015555-3726. PMID:33320272. IF:3,875.
Pereira MP, Ziehfreund S, Rueth M, Ewering T, Legat FJ, Lambert J, Elberling J, Misery L, Brenaut E, Papadavid E, Garcovich S, Evers A, Halvorsen JA, Szepietowski JC, Reich A, Goncalo M, Lvov A, Bobko S, Serra E, Wallengren J, Savk E, Leslie T, Stander S, Zink A, EADV Task Force P. Google search trends for itch in Europe: a retrospective longitudinal study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(6). DOI:10.1111/jdv.17077. PMID:33295009. IF:9,228.
Piquero-Casals J, Martínez-Martínez L, Alomar A, Rozas-Muñoz E, Juarez C, Puig L. LRP1/CD91 is highly expressed in monocytes from patients with vitiligo – even after repigmentation. Experimental Dermatology. 2021;30(3):390-395. DOI:10.1111/exd.14249. PMID: 33249636. IF:4,511.
Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina AV. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00554-4. PMID:34060012. IF:3,661.
Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021;32(5):484-491. DOI:10.1080/09546634.2019.1679336. PMID: 31613178. IF:3,230.
Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(10). DOI:10.1111/jdv.17433. PMID:34076919. IF:9,228.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Román E, Parramón M, Flavià M, Gely C, Poca M, Gallego A, Santesmases R, Hernández E, Nieto JC, Urgell E, Alvarado-Tapias E, Vidal S, Ferrero-Gregori A, Vargas V, Guarner C, Soriano G. Frailty in outpatients with cirrhosis: A prospective observational study. Liver International. 2021;41(2):357-368. DOI:10.1111/liv.14694. PMID: 33030788. IF:8,754.
Roman E, Poca M, Amoros G, Rosell J, Gely C, Nieto JC, Vidal S, Urgell E, Ferrero A, Alvarado E, Cuyas B, Hernandez E, Santesmases R, Guarner C, Escorsell A, Soriano G. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Scientific Reports. 2021; 11(1):20415. DOI:10.1038/s41598-021-99199-8. PMID:34650096. IF:4,996.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:5,197.
Rusinol L, Amat V, Baselga E, Puig L, Roe E. Prepubertal retroareolar cysts. PEDIATRIC DERMATOLOGY. 2021; 38(5). DOI:10.1111/pde.14786. PMID:34514639. IF:1,997.
Salvador JFS, Gimenez AM, de la Fuente EG, del Castillo JG, Virto A, Blanco IM, Serra E, Llorens P. Managing urticaria in the emergency department: recommendations of a multidisciplinary expert panel. Emergencias. 2021; 33(4). PMID:34251143. IF:5,345.
Sanchez MJ, Docampo A, Mercader P, Gonzalez R, Hervella M, Sanz T, Cordoba S, Sanchez J, Heras F, Gimenez AM, Gatica ME, Pastor MA, Zaragoza V, Carrascosa JM, Garcia B, Ruiz I, Borrego L, Sanchez P, Frutos JO, Armario JC, Garcia J, Fernandez V, Serra E, Silvestre JF. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. CONTACT DERMATITIS. 2021; 84(6). DOI:10.1111/cod.13801. PMID:33534191. IF:6,419.
Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. DRUGS IN R&D. 2021; 21(3). DOI:10.1007/s40268-021-00349-0. PMID:34106430. IF:3,203.
Storck M, Sandmann S, Bruland P, Pereira MP, Steinke S, Riepe C, Soto I, Garcovich S, Augustin M, Blome C, Bobko S, Legat FJ, Potekaev N, Lvov A, Misery L, Weger W, Reich A, Savk E, Streit M, Serra E, Szepietowski JC, Dugas M, Stander S, Zeidler C. Pruritus Intensity Scales across Europe: a prospective validation study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(5). DOI:10.1111/jdv.17111. PMID:33411947. IF:9,228.
Suppa M, Fontaine M, Dejonckheere G, Cinotti E, Yélamos O, Diet G, Tognetti L, Miyamoto M, Orte Cano C, Perez-Anker J, Panagiotou V, Trepant AL, Monnier J, Berot V, Puig S, Rubegni P, Malvehy J, Perrot JL, Del Marmol V. Line-field confocal optical coherence tomography of basal cell carcinoma: a descriptive study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(5):1099-1110. DOI:10.1111/jdv.17078. PMID: 33398911. IF:9,228.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Dauden E, Conrad C, Mendes P, Ferreira P, Leite L, Lu JSD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas M, del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung JN, Nogueira M, Chiricozzi A. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(4). DOI:10.1007/s40257-021-00598-4. PMID:33786754. IF:6,233.
Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy. 2021; 13(4). DOI:10.2217/imt-2020-0253. PMID:33430628. IF:4,040.
Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Review of Clinical Immunology. 2021;17(1):15-25. DOI:10.1080/1744666X.2020.1858802. PMID: 33275064. IF:5,124.
Valdivielso-Ramos M, Martin-Santiago A, Azaña JM, Hernández-Nuñez A, Vera A, Perez B, Tercedor J, Feito M, Vicente A, Prat C, Lopez-Gutierrez JC, Garnacho G, Baselga E, Roe E, Palencia S, Cordero P, Moreno R, Agudo A, de la Cueva P, Torrelo A. Capillary malformation-arteriovenous malformation syndrome: a multicentre study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2021;46(2):300-305. DOI:10.1111/ced.14428. PMID: 32840927. IF:4,481.
van KR, Tzellos T, Guillem P, Benhadou F, Cuenca C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos EJ, Jemec G, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak L, Molina A, Moltrasio C, Pinter A, Potenza C, Romani J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2021; 85(2). DOI:10.1016/j.jaad.2020.12.089. PMID:33484766. IF:15,487.
Vidal S, Puig L, Carrascosa JM, Gonzalez A, Ruiz JC, Velasco AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(13):6740. DOI:10.3390/ijms22136740. PMID:34201664. IF:6,208.
Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N, Domínguez M, Iglesias P, Herrero A, Malvehy J, Puig S. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):143-149. DOI:10.1111/jdv.16559. PMID: 32365242. IF:9,228.

Presentación

Principales líneas de investigación

Terapia biológica en dermatología.
Estudios de asociación de genoma completo en la psoriasis
Opciones de tratamiento médico y físico para tumores vasculares.
Estudios psicopatológicos de pacientes con trastornos dermatológicos crónicos.
Estudio de la inmunidad innata y adquirida en enfermedades dermatológicas mediadas inmunológicamente.

Retos

Garantizar una infraestructura de investigación clínica y personal estables.
Fomentar la colaboración científica con otros grupos del Instituto.

Equipo

Coordinación del grupo

PUIG SANZ, LUIS FGS
lpuig@santpau.cat

Miembros

Producción científica

Publicaciones 2022

(JIF 2022)

Amat V, Lopez C, Tubau C, Puig L, Serra E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1). DOI:10.1111/cod.14101. PMID:35277988. IF:5,5 (Q1/1D). Document Type: Editorial material.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12). DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3,4 (Q2/3D). Document Type: Letter.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Stakias V, Puig L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3,4 (Q2/3D). Document Type: Article.
Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Meglio PD, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Smith CH, Galloway JB, Mahil SK, PsoProtect G. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2). DOI:10.1111/bjd.21042. PMID:35104366. IF:10,3 (Q1/1D). Document Type: Letter.
Bes M, Costafreda MI, Riveiro M, Piron M, Rico A, Quer J, Puig L, Sauleda S. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. EMERGING INFECTIOUS DISEASES. 2022; 28(1). DOI:10.3201/eid2801.211466. PMID:34932460. IF:11,8 (Q1/1D). Document Type: Article.
Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4). DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13,8 (Q1/1D). Document Type: Article.
Canal E, Bosch X, Belinchon I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.006. PMID:35697407. Document Type: Review.
Carmona E, Iznardo H, Puig L. Retiform purpura in an 80-year-old woman. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2022; 61(10). DOI:10.1111/ijd.16120. PMID:35106756. IF:3,6 (Q1/3D). Document Type: Editorial material.
Carrascosa JM, Puig L, Romero IB, Salgado L, del Alcazar E, Lencina J, Moreno D, de la Cueva P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliograficas. 2022; 113(6):T583-T609. DOI:10.1016/j.ad.2022.01.024. PMID:35748004. Document type: Article/Practice Guideline.
Catala A, Munoz C, Galvan C, Riesco MR, Nebreda DR, Sola A, Giavedoni P, Llamas M, Gonzalez C, Cubiro X, Ruiz R, Gomez S, Mateo MPG, Pesque D, Marcantonio O, Fernandez D, Romani J, Pena NI, Gonzalez LC, Tercedor J, Carretero G, Masat T, Rodriguez P, Gimenez AM, Utrera M, Laguna EV, Menendez A, Lasser ES, Iglesias M, Naranjo LA, Hiltun I, Marco EC, Olabarrieta IP, Escobedo SM, Garcia X, Gutierrez MJC, Baeza G, Camps LB, Toledo T, Guilabert A. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(1). DOI:10.1111/bjd.20639. PMID:34254291. IF:10,3 (Q1/1D). Document Type: Article.
Chabra S, Gill BJ, Gallo G, Zhu DT, Pitou C, Payne CD, Accioly A, Puig L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6). DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3,8 (Q2/4D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Acosta EH, Vidal D, Vilarrasa E, Rivera R, De P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Rodriguez OB, Feltes R, Riera J, Dauden E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12):e15929. DOI:10.1111/dth.15929. PMID:36223184. IF:3,6 (Q1/3D). Document Type: Article.
Chicharro P, Llamas M, Armesto S, Herrera E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell A, Ballesca F, Belinchon I, Carretero G, Rodriguez L, Romero A, Pujol J, Salgado L, Sahuquillo A, Coto P, Baniandres O, Feltes R, Alsina M, Dauden E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8):e15653. DOI:10.1111/dth.15653. PMID:35731640. IF:3,6 (Q1/3D). Document Type: Article.
Colmenero M, del Boz J, Wittel JB, Roe E, Feito M, Vicente MA, Martin A, Perez S, Azon A, Valdivielso M, Torrelo A, Moya A, Campos M, Garnacho G, Defez J, Casano AV, Tercedor J, Alcala R, Gonzalez MA, Giacaman A, Hernandez A, Garcia MTM, Bauza A, Dominguez J, Garcia I, Grau M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4). DOI:10.1111/pde.15015. PMID:35504688. IF:1,5 (Q4/8D). Document Type: Article.
Cubiro X, Garcia C, Tubau C, Puig L. Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology Venereology & Leprology. 2022; 88(1). DOI:10.25259/IJDVL_63_2021. PMID:34623049. IF:2,9 (Q2/4D). Document Type: Letter.
de Bruin MS, Serra E, Barbarot S, Grond S, Schuster C, Petto H, Capron JP, Raibouaa A, Werfel T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6). DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3,4 (Q2/3D). Document Type: Article.
de Frutos JO, Carretero G, de Lucas R, Puig S, Serra E, Castro SG, Laserna FR, Loza E, Silvestre JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5). DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2,9 (Q2/4D). Document Type: Article.
del Alcazar E, Lopez A, Martinez A, Julia M, Ruiz R, Fernandez LR, Notario J, Llamas M, Ferran M, Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6). DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2,9 (Q2/4D). Document Type: Letter.
del Alcazar E, Lopez A, Martinez A, Ruiz R, Llamas MD, Rocamora V, Julia M, Notario J, Fernandez LR, Sahuquillo A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P, Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2):e15231. DOI:10.1111/dth.15231. PMID:34820971. IF:3,6 (Q1/3D). Document Type: Article.
Fernandez A, Ballart C, Munoz J, Basarte L, Lobato G, Arnau A, Abras A, Tebar S, Llovet T, Lami P, Pratlong F, Alsina M, Roe E, Puig L, Munoz C, Gallego M. Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. Transboundary and Emerging Diseases. 2022; 69(3). DOI:10.1111/tbed.14107. PMID:33864706. IF:4,3 (Q1/1D). Document Type: Article.
Fernandez MT, Carrato C, Saenz X, Musulen E, Fuente MJ, Puig L. MicroRNA31 and MMP-1 contribute to the differentiated pathway of invasion -with enhanced epithelial-to-mesenchymal transition- in squamous cell carcinoma of the skin. ARCHIVES OF DERMATOLOGICAL RESEARCH. 2022; 314(8). DOI:10.1007/s00403-021-02288-x. PMID:34647185. IF:3 (Q2/4D). Document Type: Article.
Gamissans M, Giavedoni P, Roe E, Sanchez J, Quintana M, Garbayo P, Vidal D, Riera N, Lopez C, Romani J, Wortsman X. Multicentric Study on High-Frequency Ultrasound Characterization of Calcium Deposits in Dermal and Subcutaneous Calciphylaxis and Calcinosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2022; 41(8). DOI:10.1002/jum.15878. PMID:34755910. IF:2,3 (Q2/5D). Document Type: Article.
Gimenez A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, Munoz F, Pedraz J, Serra E, Tejedor M, Velasco M, Terradas P, Labrador M. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022; 32(3). DOI:10.18176/jiaci.0661. PMID:33349612. IF:7,2 (Q1/2D). Document Type: Article.
Iznardo H, Bredrup C, Bernal S, Gladkauskas T, Mascaro JM, Roe E, Baselga E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4). DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2,8 (Q3/6D). Document Type: Article.
Iznardo H, Puig L. Beyond plaque psoriasis – pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4). DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5,1 (Q2/3D). Document Type: Review.
Iznardo H, Puig L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16):9479. DOI:10.3390/ijms23169479. PMID:36012744. IF:5,6 (Q1/3D). Document Type: Review.
Iznardo H, Vilarrasa E, Roe E, Puig L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18116. PMID:35353931. IF:9,2 (Q1/1D). Document Type: Letter.
Krueger J, Puig L, Thaci D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7,3 (Q1/1D). Document Type: Review.
Le AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7,3 (Q1/1D). Document Type: Review.
Lebwohl M, Langley RG, Paul C, Puig L, Reich K, van de Kerkhof P, Wu HL, Richter S, Jardon S, Gisondi P. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Dermatology and Therapy. 2022; 12(1). DOI:10.1007/s13555-021-00635-4. PMID:34704231. IF:3,4 (Q2/3D). Document Type: Article.
Lebwohl M, Soliman AM, Yang HB, Wang J, Freimark J, Puig L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(4). DOI:10.1080/09546634.2021.1919287. PMID:33899655. IF:2,9 (Q2/4D). Document Type: Article.
Lopez A, Laiz A, Puig L. Psoriatic arthritis. MEDICINA CLINICA. 2022; 159(1). DOI:10.1016/j.medcli.2022.01.024. PMID:35525675. IF:3,9 (Q2/4D). Document Type: Review.
Lopez A, Vilarrasa E, Armesto S, Santos J, Galache C, Carretero G, Sahuquillo A, Salgado L, del Alcazar E, Gonzalez A, Martorell A, Rivera R, Mitxelena J, Mateu A, Belinchon I, Llamas M, Riera J, Lazaro A, Lopez JL, Gich I, Puig L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11):e15831. DOI:10.1111/dth.15831. PMID:36109488. IF:3,6 (Q1/3D). Document Type: Letter.
Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1). DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7,3 (Q1/1D). Document Type: Review.
Medina D, Riera P, Pages N, Masip M, Lopez A, Vilarrasa E, Puig L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3). DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2,4 (Q3/8D). Document Type: Article.
Medrano RM, Estebaranz JLL, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, De Eusebio E, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, De la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Ruiz V, Sanchez P, Botella R, Gonzalez B, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, REGESMOHS Spanish Registry Mohs SU. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-Sifiliograficas. 2022; 113(5). DOI:10.1016/j.ad.2022.01.035. Document Type: Article.
Melé G, Serra E, Spertino J, Guilarte M, Ribó P, Lleonart R, Figueras I, Bonfill M, Depreux N, Sala A, Bielsa I, Baliu C, Sanmartín V, Garcia X, Expósito V, Garnica D, Diaz MC, Gómez S, Gich I, Giménez A. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(5). DOI:10.1684/ejd.2022.4334. PMID:36468733. IF:2,5 (Q2/5D). Document Type: Article.
Oro M, Gonzalez B, Sanmartin O, Garces JR, Rodriguez MA, Ruiz V, de Eusebio E, Minano R, Escutia B, Cortizas CF, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, de la Cueva P, Navarro R, Ciudad C, Carnero L, Vazquez H, Cano N, Vilarrasa E, Sanchez P, Lopez JL, Botella R, Martorell A, Gil P, Morales V, Toll A, Ocerin I, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I, Florez A. Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(1). DOI:10.1111/jdv.17597. PMID:34374137. IF:9,2 (Q1/1D). Document Type: Letter.
Pereyra J-J, Herranz P, Figuras I, Perez B, Elosua M, Munera M, Melgosa J, Zaragoza V, Silvestre JF, Campos M, Guilabert A, Miquel J, Alcantara S, De La Cueva P, Serra E, Armario JC. Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort – Real Life: Fifty-Two-Week Follow-up Results. Dermatitis. 2022; 33(6). DOI:10.1097/DER.0000000000000958. PMID:36125777. IF:5,2 (Q1/2D). Document Type: Letter.
Pinter A, Puig L, Schakel K, Reich A, Zaheri S, Costanzo A, Tsai TF, Smith SD, Lynde C, Brnabic A, Reed C, Hill J, Schuster C, Riedl E, Paul C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18376. PMID:35766124. IF:9,2 (Q1/1D). Document Type: Article.
Piron M, Jane M, Ciruela P, Basile L, Martinez A, Puig L, Bes M, Sauleda S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5). DOI:10.2450/2022.0232-21. PMID:35175189. IF:3,7 (Q2/4D). Document Type: Article.
Piron M, Salvador F, Caballero E, Sanchez A, Bes M, Casamitjana N, Puig L, Molina I, Sauleda S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9):1975. DOI:10.3390/v14091975. PMID:36146780. IF:4,7 (Q2/5D). Document Type: Article.
Puig L, Costanzo A, Munoz EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5). DOI:10.1111/bjd.20963. PMID:34939663. IF:10,3 (Q1/1D). Document Type: Review.
Puig L. Psoriasis treatment: no more room on the summit?. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(6). DOI:10.1111/bjd.21848. PMID:36065496. IF:10,3 (Q1/1D). Document Type: Editorial material.
Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3). DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2,9 (Q2/4D). Document Type: Article.
Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Saday KK, Warren RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8). DOI:10.1111/jdv.18068. PMID:35279890. IF:9,2 (Q1/1D). Document Type: Article.
Reolid A, Armesto S, Sahuquillo A, Torres T, Feltes R, Vilarrasa E, Belincho I, de la Cueva P, Rodriguez L, Romero A, Vidal D, Coto P, Herrera E, Riera J, Salgado L, Llamas M, Dauden E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3). DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13,8 (Q1/1D). Document Type: Letter.
Reymundo A, Vilarrasa E, Baniandrés O, Rodríguez L, Feltes R, Llamas M, Daudén E. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(10). DOI:10.1111/jdv.18317. PMID:35689497. IF:9,2 (Q1/1D). Document Type: Letter.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Trakatelli M, Puig L, Stratigos A, EADV Burden Skin Dis Project T. Prevalence of most common skin diseases in Europe: a population-based study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(7). DOI:10.1111/jdv.18050. PMID:35274366. IF:9,2 (Q1/1D). Document Type: Article.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:3,4 (Q2/3D). Document Type: Article.
Rusinol L, Camina G, Puig L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12). DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4,6 (Q2/3D). Document Type: Article.
Sánchez G, Puig L. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6). DOI:10.1016/j.piel.2021.06.020. Document Type: Article.
Sans L, Figueras I, Bonfill M, De Jesus C, Garcia I, Guilabert A, Curto L, Bertolin M, Ferran M, Serra E, Zalewska A, Wang YH, Howell MD, Pujol RM, Santamaria LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11). DOI:10.1111/all.15424. PMID:35773619. IF:12,4 (Q1/1D). Document Type: Letter.
Sanz C, Nomdedeu M, Pereira A, Sauleda S, Alonso R, Bes M, Brillembourg H, Garcia C, Millan A, Martinez N, Piron M, Puerta P, Puig L, Rico V, Soriano A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5). DOI:10.1111/trf.16863. PMID:35338710. IF:2,9 (Q3/7D). Document Type: Article.
Serra E, Santamaria LF, Silvestre JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7). DOI:10.1016/j.ad.2021.12.014. PMID:35842249. Document Type: Review.
Thaci D, Gerdes S, Du KG, Perrot JL, Puig L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10). DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3,4 (Q2/3D). Document Type: Article.
Thaci D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye JN, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2). DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3,4 (Q2/3D). Document Type: Article.
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova I, Arents BWM, Bauer A, Brans R, Cannavo A, Christoffers WA, Crépy M-N, Elsner P, Fartasch M, Filon FL, Giménez AM, Gonçalo M, Guzmán MG, Hamann CR, Hoetzenecker W, Johansen JD, John SM, Kunkeler ACM, Hadzavdic SL, Molin S, Nixon R, Oosterhaven JAF, Rustemeyer T, Serra E, Shah M, Simon D, Skudlik C, Spiewak R, Valiukeviciene S, Voorberg AN, Weisshaar E, Agner T. Guidelines for diagnosis, prevention, and treatment of hand eczema. CONTACT DERMATITIS. 2022; 86(5). DOI:10.1111/cod.14035. PMID:34971008. IF:5,5 (Q1/1D). Document Type: Article/Practice Guideline.
Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, del Alcazar E, Rull EV, Llamas M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6). DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7,3 (Q1/1D). Document Type: Article.
Tubau C, Cubiro X, Amat V, Garcia C, Puig L, Roe E. Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal Of Ultrasound. 2022; 25(4). DOI:10.1007/s40477-022-00665-4. PMID:35397096. Document Type: Article.
Van AM, Menting SP, Gyulai R, Iversen L, Van Der Kraaij GE, Middelkamp MA, Warren RB, Spuls PI, Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse A-C, Carija A, Akman A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado C, Hong C-H, et al. [Vilarrasa E, Puig L]. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5). DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10,9 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9). DOI:10.1111/jdv.18345. PMID:35980214. IF:9,2 (Q1/1D). Document Type: Article.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, Bieber T, Brough HA, Pinton PC, Christen S, Deleuran M, Dittmann M, Dressler C, Fink AH, Fosse N, Gaspar K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, Serra E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11). DOI:10.1111/jdv.18429. PMID:36056736. IF:9,2 (Q1/1D). Document Type: Article.
Zachariae C, Mrowietz U, Strodl J, Puig L. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4). DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2,5 (Q2/5D). Document Type: Article.
Zozaya N, Abdalla F, Zamora SA, Filgueiras JB, Carrillo JMC, Sanchez OD, Sinisterra FD, Garcia A, Pinto PH, Manfredi A, Olmos JM, Luna PMD, Puig L, Ros S, HIdalgo A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6). DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2,3 (Q3/7D). Document Type: Article.
Zozaya N, Villoro R, Abdalla F, Alfonso S, Balea J, Carrascosa JM, Delgado O, Dolz F, Garcia A, Herranz P, Manfredi A, Martinez J, Morales De los Rios Luna P, Puig L, Ros S, Hildago A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102:adv00678. DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3,6 (Q1/3D). Document Type: Article.

Publicaciones 2021

Amat V, Agut E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211055920. DOI:10.1177/20406223211055920. PMID:34840709. IF:4,970.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao YW, Puig L, Augustin M. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00511-1. PMID:33788177. IF:3,661.
Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(4). DOI:10.1111/jdv.17075. PMID:33533553. IF:9,228.
Buhl T, Rosmarin D, Serra E, Fernandez P, Igarashi A, Konstantinou MP, Chen S, Lu N, Pierce E, Casillas M. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy. 2021; 11(3). DOI:10.1007/s13555-021-00534-8. PMID:33899152. IF:3,661.
Campos MC, Tubau C, Segura S, Gonzalez M, Iglesias M, Fernandez MT, Garcia MP, Mozos A. Oral submucous fibrosis presenting with histopathological lichenoid changes as predominant feature: Report of five cases and review of the literature. JOURNAL OF CUTANEOUS PATHOLOGY. 2021; 48(11). DOI:10.1111/cup.14084. PMID:34151457. IF:1,458.
Carretero G, Carrascosa JM, Puig L, Sánchez-Carazo JL, López-Ferrer A, Cueva P, Soria C, Rivera R, Belinchón I; Psoriasis Group of the Spanish Academy of Dermatology, Venereology. Definition of minimal disease activity in psoriasis. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(2):422-430. DOI:10.1111/jdv.16564. PMID: 32367536. IF:9,228.
Cubiro X, Garcia C, Morales CE, Roe E, Riera A, Mora JM, Iriarte A, Puig L, Baselga E. Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. Dermatologic Therapy. 2021; 34(6):e15124. DOI:10.1111/dth.15124. PMID:34486206. IF:3,858.
de Bruin M, Merola JF, Hong CH, Baldrich ES, Ettler K, Sierka D, Delevry D, Chen Z, Rossi AB. Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective. Dermatology and Therapy. 2021; 11(6). DOI:10.1007/s13555-021-00621-w. PMID:34767181. IF:3,661.
Galvan C, Mitja O, Esteban S, Kafulafula J, Phiri T, Navarro I, Roman C, Mtenje H, Thauzeni G, Harawa E, Kaluzi S, Diere M, Mkandawire M, Malizani S, Chifundo A, Utrera M, Roncero M, Martin SL, Vilanova I, Petiti GH, Aranda MVD, Perez NN, Gomez MR, Iranzo P, Garcia PE, De Troya M, Gomez JR, Cardenoso E, Truyols SL, Unanue LA, et al. [Cubiro X, Lopez C]. A facility and community-based assessment of scabies in rural Malawi. PLoS Neglected Tropical Diseases. 2021; 15(6):e0009386. DOI:10.1371/journal.pntd.0009386. PMID:34061851. IF:4,781.
Garcia C, Roe E, Rodriguez B, Amat V, Cubiro X, Puig L, Boronat S. A case report of PHF6 mosaicism: Beyond the classic Borjeson-Forssman-Lehmann syndrome. PEDIATRIC DERMATOLOGY. 2021; 38(4). DOI:10.1111/pde.14636. PMID:34041787. IF:1,997.
Garcia J, Delgadillo J, Vilarrodona A, Querol S, Ovejo J, Coll R, Millan A, Madrigal A, Soria G, Vidal F, Vives J, Herrero MJ, Lopez I, Sauleda S, Contreras E, Grifols JR, Guasch R, Tahull E, Puig L, Masip A, Argelagues E, Muniz E. SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfusion. 2021; 19(2). DOI:10.2450/2021.0259-20. PMID:33539280. IF:5,752.
García-Martínez FJ, Vilarrasa E, Salgado-Boquete L, Martorell A, Pascual JC, Hernández-Martín Á, Silvente C, Ciudad-Blanco C, Andrés Esteban E, Alfageme-Roldán F. Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021y;32(3):286-290. DOI:10.1080/09546634.2019.1655524. PMID: 31402725. IF:3,230.
Girolomoni G, de Bruin M, Aoki V, Kabashima K, Deleuran M, Puig L, Bansal A, Rossi AB. Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211002979. DOI:10.1177/20406223211002979. PMID:33854747. IF:4,970.
Gomis-Pastor M, Mirabet Perez S, Roig Minguell E, Brossa Loidi V, Lopez Lopez L, Ros Abarca S, Galvez Tugas E, Mas-Malagarriga N, Mangues Bafalluy MA. Mobile Health to Improve Adherence and Patient Experience in Heart Transplantation Recipients: The mHeart Trial. Healthcare (Basel). 2021;9(4):463. DOI:10.3390/healthcare9040463. PMID: 33919899. IF:3,160.
González-Manso A, Agut-Busquet E, Romaní J, Vilarrasa E, Bittencourt F, Mensa A, Cantó E, Aróstegui JI, Vidal S. Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis. Dermatology. 2021;237(3):365-371. DOI:10.1159/000511045. PMID: 33171462. IF:5,197.
Iznardo H, Baselga E, Mozos A, Szafranska J, Orellana R, Roe E. Net-like superficial lymphatic malformation. PEDIATRIC DERMATOLOGY. 2021; 38(2). DOI:10.1111/pde.14526. PMID:33486776. IF:1,997.
Iznardo H, Puig L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic Advances in Chronic Disease. 2021; 12:20406223211037846. DOI:10.1177/20406223211037846. PMID:34408825. IF:4,970.
Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(9):4344. DOI:10.3390/ijms22094344. PMID:33919434. IF:6,208.
Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Review of Clinical Immunology. 2021; 17(2). DOI:10.1080/1744666X.2021.1886081. PMID:33538202. IF:5,124.
Julia A, Martinez SH, Domenech E, Canete JD, Ferrandiz C, Tornero J, Gisbert JP, Fernandez A, Dauden E, Barreiro M, Perez C, Queiro R, Lopez FJ, Carazo JLS, Mendoza JL, Alperi M, Montilla C, Venegas JJP, Munoz F, Castaneda S, Lasanta ML, Marsal S, Fonseca E, Rodriguez J, Carreira P, Garcia V, Pinto JA, Puig L, Ricart E, Blanco F, Gratacos J, et al. [Garcia E, Diaz C]. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2021; 75(9). DOI:10.1038/s41430-021-00913-6. PMID:33893449. IF:4,884.
Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, Peter J, Comert-Ozer E, Abuzakouk M, Agondi RC, Al-Ahmad M, Altrichter S, Arnaout R, Arruda LK, Asero R, Bauer A, Ben-Shoshan M, Bernstein JA, Bizjak M, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Busse P, Campos RA, Carne E, Conlon N, Criado RF, de Souza Lima EM, Demir S, et al. [Serra-Baldrich E]. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76(3):816-830. DOI:10.1111/all.14687. PMID: 33284457. IF:14,710.
Lambert J, Hansen JB, Sohrt A, Puig L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00545-5. PMID:33988818. IF:3,661.
Llao J, Masnou H, Romero C, Bargallo A, Gely C, Manosa M, Gordillo J, Garcia E, Domenech E. Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 2021; 33(6). DOI:10.1097/MEG.0000000000001799. PMID:32804842. IF:2,586.
Lopez C, Falla LM, Roe E, Arostegui JI, Mozos A, Bernal S, Iznardo H, Baselga E. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. JOURNAL OF DERMATOLOGY. 2021; 48(6). DOI:10.1111/1346-8138.15673. PMID:33543522. IF:3,468.
Lopez C, Romani J, Garbayo P, Agut E. Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. JOURNAL OF DERMATOLOGY. 2021; 48(4). DOI:10.1111/1346-8138.15728. PMID:33547675. IF:3,468.
Lopez C, Romani J, Roe E, Giavedoni P, Vidal D, Wortsman X. Ultrasonographic patterns of cutaneous sarcoidosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2021; 40(11). DOI:10.1002/jum.15631. PMID:33459396. IF:2,754.
Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di P, Langan SM, Capon F, et al.; PsoProtect GRP. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2021; 147(1). DOI:10.1016/j.jaci.2020.10.007. PMID:33075408. IF:14,290.
Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, de la Cruz C, Di P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, et al.; PsoProtect CORE GRP. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(1). DOI:10.1111/bjd.19755. PMID:33368145. IF:11,113.
Marron SE, Gomez M, Aragones LT, Goni A, Vilarrasa E, Diaz RM, Garcia FJ, Campos R, Fuentelsaz V, Gilaberte Y, Gracia T, Morales AM, Ros S, Madrid MB, Puig L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv00529. DOI:10.2340/00015555-3905. PMID:34427316. IF:3,875.
Massey PR, Schmults CD, Li SJ, Arron ST, Asgari MM, Bavinck JNB, Billingsley E, Blalock TW, Blasdale K, Carroll BT, Carucci JA, Chong AH, Christensen SR, Chung CL, DeSimone JA, Ducroux E, Escutia B, Ferrandiz C, Fox MC, Genders RE, Geusau A, Gjersvik P, Hanlon AM, Harken E, Hofbauer GFL, Hopkins RS, Leitenberger JJ, Loss MJ, Del Marmol V, et al. [Ruiz V]. Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients A Delphi Consensus Statement. JAMA Dermatology. 2021; 157(10). DOI:10.1001/jamadermatol.2021.3180. PMID:34468690. IF:11,816.
Mogedas A, Agut E, Marsal MY, Aguilar JL, de la Torre OE. Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021; 79(12). DOI:10.1016/j.joms.2021.07.009. PMID:34391723. IF:2,136.
Muniz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, Millan A, Ene G, Ramiro L, Maglio L, Garcia N, Pinacho A, Jaramillo A, Pero A, Artaza G, Valles R, Sauleda S, Puig L, Contreras E. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfusion. 2021; 19(1). DOI:10.2450/2020.0256-20. PMID:33196417. IF:5,752.
Munoz FZ, Rios M, Roe E, Bernabeu J, Montserrat MT, Puig L, Gich I, Baselga E. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage A Randomized Clinical Trial. JAMA Dermatology. 2021; 157(5). DOI:10.1001/jamadermatol.2021.0596. PMID:33825828. IF:11,816.
Nieto LM, Ciudad C, Sanmartin O, Garces JR, Rodriguez MA, Vilarrasa E, de Eusebio E, Minano R, Escutia B, Gonzalez B, Artola JL, Rubio AA, Redondo P, Delgado Y, Sanchez JM, Allende I, Alonso ML, Garcia B, Dobao PD, Navarro R, Suarez R, Carnero L, Vazquez H, Barchino L, Ruiz V, Sanchez P, Lopez JL, Botella R, Feal C, Calatayud AM, Gil P, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. EXPERIMENTAL DERMATOLOGY. 2021; 30(5). DOI:10.1111/exd.14291. PMID:33523531. IF:4,511.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(6). DOI:10.1111/bjd.20595. PMID:34157132. IF:11,113.
Papp KA, Soliman AM, Done N, Carley C, Wirtz EL, Puig L. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00550-8. PMID:34019229. IF:3,661.
Pereira MP, Zeidler C, Wallengren J, Halvorsen JA, Weisshaar E, Garcovich S, Misery L, Brenaut E, Savk E, Potekaev N, Lvov A, Bobko S, Szepietowski JC, Reich A, Bozek A, Legat FJ, Metz M, Streit M, Serra E, Goncalo M, Storck M, Nau T, Hoffmann V, Steinke S, Greiwe I, Dugas M, Augustin M, Stander S, European Prurigo Project Epp C. Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. ACTA DERMATO-VENEREOLOGICA. 2021; 101:adv000403. DOI:10.2340/00015555-3726. PMID:33320272. IF:3,875.
Pereira MP, Ziehfreund S, Rueth M, Ewering T, Legat FJ, Lambert J, Elberling J, Misery L, Brenaut E, Papadavid E, Garcovich S, Evers A, Halvorsen JA, Szepietowski JC, Reich A, Goncalo M, Lvov A, Bobko S, Serra E, Wallengren J, Savk E, Leslie T, Stander S, Zink A, EADV Task Force P. Google search trends for itch in Europe: a retrospective longitudinal study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(6). DOI:10.1111/jdv.17077. PMID:33295009. IF:9,228.
Piquero-Casals J, Martínez-Martínez L, Alomar A, Rozas-Muñoz E, Juarez C, Puig L. LRP1/CD91 is highly expressed in monocytes from patients with vitiligo – even after repigmentation. Experimental Dermatology. 2021;30(3):390-395. DOI:10.1111/exd.14249. PMID: 33249636. IF:4,511.
Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina AV. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatology and Therapy. 2021; 11(4). DOI:10.1007/s13555-021-00554-4. PMID:34060012. IF:3,661.
Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. JOURNAL OF DERMATOLOGICAL TREATMENT. 2021;32(5):484-491. DOI:10.1080/09546634.2019.1679336. PMID: 31613178. IF:3,230.
Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(10). DOI:10.1111/jdv.17433. PMID:34076919. IF:9,228.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Román E, Parramón M, Flavià M, Gely C, Poca M, Gallego A, Santesmases R, Hernández E, Nieto JC, Urgell E, Alvarado-Tapias E, Vidal S, Ferrero-Gregori A, Vargas V, Guarner C, Soriano G. Frailty in outpatients with cirrhosis: A prospective observational study. Liver International. 2021;41(2):357-368. DOI:10.1111/liv.14694. PMID: 33030788. IF:8,754.
Roman E, Poca M, Amoros G, Rosell J, Gely C, Nieto JC, Vidal S, Urgell E, Ferrero A, Alvarado E, Cuyas B, Hernandez E, Santesmases R, Guarner C, Escorsell A, Soriano G. Phase angle by electrical bioimpedance is a predictive factor of hospitalisation, falls and mortality in patients with cirrhosis. Scientific Reports. 2021; 11(1):20415. DOI:10.1038/s41598-021-99199-8. PMID:34650096. IF:4,996.
Ruiz V, Sanmartin O, Garces JR, Vilarrasa E, Minano R, Escutia B, Florez A, Artola JL, Alfaro A, Redondo P, Delgado Y, Sanchez J, Allende I, Bracamonte BG, de la Cueva P, Ciudad C, Carnero L, Vazquez H, Sanchez P, Estebaranz JL, Botella R, Gonzalez B, Martorell A, Morales V, Toll A, Mayor M, Suarez R, Sainz L, Descalzo MA, Garcia I. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS. DERMATOLOGY. 2022; 238(2). DOI:10.1159/000517010. PMID:34380138. IF:5,197.
Rusinol L, Amat V, Baselga E, Puig L, Roe E. Prepubertal retroareolar cysts. PEDIATRIC DERMATOLOGY. 2021; 38(5). DOI:10.1111/pde.14786. PMID:34514639. IF:1,997.
Salvador JFS, Gimenez AM, de la Fuente EG, del Castillo JG, Virto A, Blanco IM, Serra E, Llorens P. Managing urticaria in the emergency department: recommendations of a multidisciplinary expert panel. Emergencias. 2021; 33(4). PMID:34251143. IF:5,345.
Sanchez MJ, Docampo A, Mercader P, Gonzalez R, Hervella M, Sanz T, Cordoba S, Sanchez J, Heras F, Gimenez AM, Gatica ME, Pastor MA, Zaragoza V, Carrascosa JM, Garcia B, Ruiz I, Borrego L, Sanchez P, Frutos JO, Armario JC, Garcia J, Fernandez V, Serra E, Silvestre JF. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. CONTACT DERMATITIS. 2021; 84(6). DOI:10.1111/cod.13801. PMID:33534191. IF:6,419.
Speeckaert R, Lambert J, Puig L, Speeckaert M, Lapeere H, De Schepper S, van N. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. DRUGS IN R&D. 2021; 21(3). DOI:10.1007/s40268-021-00349-0. PMID:34106430. IF:3,203.
Storck M, Sandmann S, Bruland P, Pereira MP, Steinke S, Riepe C, Soto I, Garcovich S, Augustin M, Blome C, Bobko S, Legat FJ, Potekaev N, Lvov A, Misery L, Weger W, Reich A, Savk E, Streit M, Serra E, Szepietowski JC, Dugas M, Stander S, Zeidler C. Pruritus Intensity Scales across Europe: a prospective validation study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(5). DOI:10.1111/jdv.17111. PMID:33411947. IF:9,228.
Suppa M, Fontaine M, Dejonckheere G, Cinotti E, Yélamos O, Diet G, Tognetti L, Miyamoto M, Orte Cano C, Perez-Anker J, Panagiotou V, Trepant AL, Monnier J, Berot V, Puig S, Rubegni P, Malvehy J, Perrot JL, Del Marmol V. Line-field confocal optical coherence tomography of basal cell carcinoma: a descriptive study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(5):1099-1110. DOI:10.1111/jdv.17078. PMID: 33398911. IF:9,228.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, Gisondi P, Dauden E, Conrad C, Mendes P, Ferreira P, Leite L, Lu JSD, Valerio J, Bruni M, Messina F, Nidegger A, Llamas M, del Alcazar E, Mufti A, White K, Caldarola G, Teixeira L, Romanelli P, Desai K, Gkalpakiotis S, Romanelli M, Yeung JN, Nogueira M, Chiricozzi A. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(4). DOI:10.1007/s40257-021-00598-4. PMID:33786754. IF:6,233.
Tubau C, Puig L. IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy. 2021; 13(4). DOI:10.2217/imt-2020-0253. PMID:33430628. IF:4,040.
Tubau C, Puig L. Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert Review of Clinical Immunology. 2021;17(1):15-25. DOI:10.1080/1744666X.2020.1858802. PMID: 33275064. IF:5,124.
Valdivielso-Ramos M, Martin-Santiago A, Azaña JM, Hernández-Nuñez A, Vera A, Perez B, Tercedor J, Feito M, Vicente A, Prat C, Lopez-Gutierrez JC, Garnacho G, Baselga E, Roe E, Palencia S, Cordero P, Moreno R, Agudo A, de la Cueva P, Torrelo A. Capillary malformation-arteriovenous malformation syndrome: a multicentre study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2021;46(2):300-305. DOI:10.1111/ced.14428. PMID: 32840927. IF:4,481.
van KR, Tzellos T, Guillem P, Benhadou F, Cuenca C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos EJ, Jemec G, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak L, Molina A, Moltrasio C, Pinter A, Potenza C, Romani J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2021; 85(2). DOI:10.1016/j.jaad.2020.12.089. PMID:33484766. IF:15,487.
Vidal S, Puig L, Carrascosa JM, Gonzalez A, Ruiz JC, Velasco AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(13):6740. DOI:10.3390/ijms22136740. PMID:34201664. IF:6,208.
Yélamos O, Alejo B, Ertekin SS, Villa-Crespo L, Zamora-Barquero S, Martinez N, Domínguez M, Iglesias P, Herrero A, Malvehy J, Puig S. Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):143-149. DOI:10.1111/jdv.16559. PMID: 32365242. IF:9,228.

GRUPOS ASOCIADOS

Dermatología

Principales líneas de investigación

Retos

Coordinación del grupo

Miembros

Publicaciones 2022

Publicaciones 2021

Principales líneas de investigación

Retos

Coordinación del grupo

Miembros

Publicaciones 2022

Publicaciones 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau